What did @ivanmartellato actually say?
Honestly, the transcript here is nearly unintelligible. The auto-generated captions produced something about being "from the laboratory O'Reilly" and playing "a new show," which bears no resemblance to a coherent health claim. What we can work with are the hashtags, which are doing real promotional work: #ghkcu, #tb500, #bpc157, #curcumina, #boswellia, #mirra (myrrh), all grouped under the theme of "integrazione contro l'infiammazione" (supplementation against inflammation) with a ligament-focused angle.
So the actual argument being advanced, even if never stated clearly in the transcript, appears to be: these compounds, taken together or individually, reduce inflammation and support ligament recovery. That is the claim we need to examine, because 40,000 viewers are reading those hashtags as recommendations.
Does the science back this up?
Partially, and with significant asterisks depending on which compound you are looking at. The natural anti-inflammatories have the clearest human evidence. The peptides are a different story entirely.
Curcumin has credible, if modest, human trial support. A 2017 meta-analysis by Daily et al. in the Journal of Medicinal Food found bioavailable curcumin formulations produced statistically significant reductions in inflammatory markers including CRP and IL-6. Effect sizes were real but not dramatic. Boswellia serrata has similarly useful data: a 2011 RCT by Sontakke et al. in the Indian Journal of Pharmacology found AKBA-enriched boswellia extract outperformed placebo for knee osteoarthritis pain. Myrrh (mirra) is the weakest link here: its anti-inflammatory properties are mostly demonstrated in cell cultures and animal models, not controlled human trials.
BPC-157 and TB-500 are where the evidentiary floor drops. Both have genuinely interesting animal data. Sikiric et al. have published extensively on BPC-157's tendon and ligament repair effects in rodents across multiple journals including Journal of Physiology-Paris. TB-500 (a thymosin beta-4 fragment) shows similar preclinical promise. But neither compound has completed Phase II human trials. GHK-Cu peptide has reasonable human skin data but almost no controlled ligament or systemic inflammation data in humans.
What did they get wrong (or right)?
The framing gets something right and something dangerously incomplete. Pairing natural anti-inflammatories like curcumin and boswellia with a recovery protocol is not unreasonable. The evidence base for those two specifically is real enough that dismissing them entirely would be unfair.
What the video gets wrong, or at least what the hashtag stack implies without caveat, is treating BPC-157 and TB-500 as equivalent players in an anti-inflammation lineup. They are not legally in the same category. In most jurisdictions including the EU (where an Italian creator is likely operating), these peptides are not approved pharmaceuticals and are not legal for human use outside of a supervised clinical context. The FDA placed BPC-157 on its list of substances withdrawn from the bulk drug substances list in 2022, meaning compounded BPC-157 for human use is not permitted in the US.
Lumping peptides with supplement-grade botanicals under one hashtag, without that legal and evidentiary distinction, is misleading by omission. That is a problem regardless of whether the transcript was coherently captured.
What should you actually know?
If you are dealing with ligament inflammation, the honest hierarchy of evidence looks like this: curcumin with enhanced bioavailability (phospholipid complex or nanoparticle formulation) and boswellia serrata with standardized AKBA content are the compounds with the clearest risk-benefit profile for most adults. Neither replaces medical evaluation for acute ligament injury.
BPC-157 and TB-500 are being used by athletes and biohackers, that is simply true. The animal data is legitimately interesting and some researchers argue human trials are overdue. But "interesting preclinical data" is not the same as "safe and effective for human use," and the regulatory status matters. Anyone pursuing these compounds should understand they are operating outside approved medical use in most countries, and the long-term human safety data does not exist yet.
GHK-Cu applied topically has the cleanest regulatory pathway and the most human evidence, mostly in wound healing contexts. Its systemic anti-inflammatory role in ligament tissue is speculative at this stage.
Always consult a physician or licensed clinician before adding any of these compounds to a recovery protocol. A hashtag stack is not a prescription.